Firm to market breast cancer drug in MEJapan-based Eisai will market its breast cancer treatment Halaven (eribulin) in selected countries within the Middle East region through a new partnership between Eisai EMEA and NewBridge Pharmaceuticals. Eribulin is indicated for More… |
Eisai's breast cancer drug ‘extends lives’Eisai's experimental breast cancer drug eribulin added an average of two and a half months to the lives of patients dying of breast cancer, which is a big improvement in such seriously ill cancer patients, researchers said. The results of More… |